Sodium glycerophosphate

# Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider.  WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery.  The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements.  WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

# Overview
Sodium glycerophosphate is a potassium supplement that is FDA approved for the prophylaxis of adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.   Common adverse reactions include absence of drug reaction.

# Adult Indications and Dosage

## FDA-Labeled Indications and Dosage (Adult)
- Sodium glycerophosphate  is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.

### Posology and method of administration
- Sodium glycerophosphate must not be given undiluted.
- The recommended dosage is individual. The recommended daily dosage of phosphate during intravenous nutrition would normally be 10-20 mmol. This can be met by using 10-20 ml of sodium glycerophosphate added to the infusion solution or to the admixture for which compatibility has been proved.

## Off-Label Use and Dosage (Adult)

### Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Sodium glycerophosphate in adult patients.

### NonGuideline-Supported Use
There is limited information regarding Off-Label NonGuideline-Supported Use of Sodium glycerophosphate in adult patients.

# Pediatric Indications and Dosage

## FDA-Labeled Indications and Dosage (Pediatric)
- sodium glycerophosphate is indicated in adult patients and infants as a supplement in intravenous nutrition to meet the requirements of phosphate.

### Posology and method of administration
- Sodium glycerophosphate must not be given undiluted.
- The recommended dosage is individual. The recommended dose for infants and neonates is 1.0-1.5 mmol/Kg body weight/day.

## Off-Label Use and Dosage (Pediatric)

### Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Sodium glycerophosphate in pediatric patients.

### NonGuideline-Supported Use
There is limited information regarding Off-Label NonGuideline-Supported Use of Sodium glycerophosphate in pediatric patients.

# Contraindications
- sodium glycerophosphate should not be given to patients in a state of dehydration or with hypernatraemia, hyperphosphataemia, severe renal insufficiency or shock.

# Warnings
- sodium glycerophosphate should be used with caution in patients with impaired renal function. The phosphate status of all patients should be monitored regularly.
sodium glycerophosphate must not be given undiluted.

# Adverse Reactions

## Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Sodium glycerophosphate in the drug label.

## Postmarketing Experience
There is limited information regarding Postmarketing Experience of Sodium glycerophosphate in the drug label.

# Drug Interactions
- No interactions with other drugs have been observed, but a moderate fall in serum phosphate can be seen during carbohydrate infusions.

# Use in Specific Populations

### Pregnancy
Pregnancy Category (FDA):
- Animal reproduction studies or clinical investigations during pregnancy have not been carried out with sodium glycerophosphate. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.No adverse events are to be expected when sodium glycerophosphate is administered during pregnancy.
Pregnancy Category (AUS): 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Sodium glycerophosphate in women who are pregnant.

### Labor and Delivery
There is no FDA guidance on use of Sodium glycerophosphate during labor and delivery.

### Nursing Mothers
- Animal reproduction studies or clinical investigations during pregnancy have not been carried out with sodium glycerophosphate. However, the requirements of phosphate in a pregnant woman are slightly increased compared to non-pregnant women.
- No adverse events are to be expected when sodium glycerophosphate is administered during pregnancy.

### Pediatric Use
There is no FDA guidance on the use of Sodium glycerophosphate with respect to pediatric patients.

### Geriatic Use
There is no FDA guidance on the use of Sodium glycerophosphate with respect to geriatric patients.

### Gender
There is no FDA guidance on the use of Sodium glycerophosphate with respect to specific gender populations.

### Race
There is no FDA guidance on the use of Sodium glycerophosphate with respect to specific racial populations.

### Renal Impairment
There is no FDA guidance on the use of Sodium glycerophosphate in patients with renal impairment.

### Hepatic Impairment
There is no FDA guidance on the use of Sodium glycerophosphate in patients with hepatic impairment.

### Females of Reproductive Potential and Males
There is no FDA guidance on the use of Sodium glycerophosphate in women of reproductive potentials and males.

### Immunocompromised Patients
There is no FDA guidance one the use of Sodium glycerophosphate in patients who are immunocompromised.

# Administration and Monitoring

### Administration
- Intravenous

### Monitoring
There is limited information regarding Monitoring of Sodium glycerophosphate in the drug label.

# IV Compatibility
There is limited information regarding IV Compatibility of Sodium glycerophosphate in the drug label.

# Overdosage
- No adverse effects of an overdose have been reported. Most patients in need of intravenous nutrition have an increased capacity to handle glycerophosphate.

# Pharmacology
There is limited information regarding Sodium glycerophosphate Pharmacology in the drug label.

## Mechanism of Action
There is limited information regarding Sodium glycerophosphate Mechanism of Action in the drug label.

## Structure
- The active ingredient in 1 ml of sodium glycerophosphate correspond to
- Phosphate        1 mmol
- Sodium            2 mmol

## Pharmacodynamics
- Glycerophosphate is a metabolic intermediate in fat metabolism and any pharmacodynamic effects other than maintaining the normal metabolic pathways are unlikely.

## Pharmacokinetics
- To become available it is necessary for the phosphate group to be hydrolysed from the glycerophosphate molecule. The hydrolysis occurs maximally at a plasma concentration of >0.7 mmol/l. Assuming that all hydrolysis of glycerophosphate takes place in plasma, about 12-15 mmol of sodium glycerophosphate will be hydrolysed each day in individuals with normal serum alkaline phosphatase.
- No pharmacokinetical data is available for infants, however with the recommended dosage hyperphosphataemia is unlikely.

## Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Sodium glycerophosphate in the drug label.

# Clinical Studies
There is limited information regarding Clinical Studies of Sodium glycerophosphate in the drug label.

# How Supplied
- sodium glycerophosphate may only be added to or mixed with other medicinal products for which compatibility has been documented. See 5.6.
- Shelf life is 3 years
- Special precautions for storage
- Do not store above 25C. Do not freeze.
- Nature and contents of container
- Pack size: 10 x 20 ml
- Instructions for use/handling
- sodium glycerophosphate must not be given undiluted.

## Storage
There is limited information regarding Sodium glycerophosphate Storage in the drug label.

# Images

## Drug Images

## Package and Label Display Panel

# Patient Counseling Information
There is limited information regarding Patient Counseling Information of Sodium glycerophosphate in the drug label.

# Precautions with Alcohol
- Alcohol-Sodium glycerophosphate interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

# Brand Names
- Glycophos

# Look-Alike Drug Names
There is limited information regarding Sodium glycerophosphate Look-Alike Drug Names in the drug label.

# Drug Shortage Status

# Price